IMMIX BIOPHARMA, INC.
11400 West Olympic Blvd., Suite 200
Los Angeles, CA 90064
VIA EDGAR
September 26, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Immix Biopharma, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed September 25, 2023
File No. 333-274684
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Immix Biopharma, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to September 28, 2023, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Melanie R. Levy of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. at (858) 314 -1873.
| Sincerely, | |
| IMMIX BIOPHARMA, INC. | |
| /s/ Gabriel Morris | |
| Gabriel Morris | |
| Chief Financial Officer |
cc: Ilya Rachman, Immix Biopharma, Inc.
Melanie R. Levy, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.